- The overdose of drugs in Japan Nature
Fukushima M. Nature. 1989;342(6252):850-851. doi:10.1038/342850a0
https://www.nature.com/articles/342850a0 - Clinical trials in Japan
Fukushima M. Nat Med 1, 12–13 (1995). https://doi.org/10.1038/nm0195-12 - Projection of creutzfeldt-jakob disease frequency based on cadaveric dura transplantation in Japan
Hamada C, Sadaike T, Fukushima M. Neuroepidemiology. 2003;22(1):57-64. doi:10.1159/000067103
https://pubmed.ncbi.nlm.nih.gov/12566955/ - Creutzfeldt-Jakob Disease and Cadaveric Dura Mater Grafts in Japan: An Updated Analysis of Incubation Time
Shigeyuki Matsui, Tetsuji Sadaike, Chikuma Hamada, Masanori Fukushima; Neuroepidemiology
1 December 2004; 24 (1-2): 22–25. https://doi.org/10.1159/000081045 - Size of Creutzfeldt-Jakob disease epidemic associated with cadaveric dura transplantation
Tanaka S, Fukushima M. Neuroepidemiology. 2010;34(4):232-237. doi:10.1159/00029774
https://pubmed.ncbi.nlm.nih.gov/20299804/ - Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures
Nishimura T, Tada H, Nakagawa M, Teramukai S, Matsui S, Fukushima M. Pharm Pract (Granada). 2006;4(4):168-178.
doi:10.4321/s1885-642×2006000400004 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155619/ - Lessons from Gefitinib-induced Interstitial Lung Disease: Pharmacovigilance for Erlotinib in Japan
Nishimura, Tsutomu, Tada, Harue, and Fukushima, Masanori. 1 Jan. 2009 : 161 – 167.
https://content.iospress.com/articles/international-journal-of-risk-and-safety-in-medicine/jrs475
